Fig. 2

Apatinib inhibited esophageal cancer cell growth via promoting cell apoptosis and suppressing cell cycle progression in vitro. a Cell viability of KYSE30 and TE1 cell lines detected by a CCK-8 kit after apatinib treatment (1, 3, 10, 30 and 100 μM) for the indicated time. P values were determined by one-way ANOVA with Tukey’s correction. *P < 0.05, **P < 0.01. b Colony formation ability of KYSE30 and TE1 cells was inhibited by apatinib (3, 10 and 30 μM). c Quantitative analysis of the number of colonies. P values were determined by one-way ANOVA with Tukey’s correction. *P < 0.05, **P < 0.01. d KYSE30 and TE1 cells were treated with apatinib (3, 10 and 30 μM) for 36 h. Apoptosis was determined by flow cytometry. e Quantitative analysis of the apoptotic rate. P values were determined by one-way ANOVA with Tukey’s correction. *P < 0.05, **P < 0.01. f KYSE30 and TE1 cells were treated with apatinib (3, 10 and 30 μM) for 36 h. The number of cells in different stages of the cell cycle was determined by flow cytometry. g Quantitative analysis of cell cycle distribution. P values were determined by one-way ANOVA with Tukey’s correction. *P < 0.05, **P < 0.01. h KYSE30 and TE1 cells were treated with apatinib (10 μM) for 24 h. The protein levels of Survivin, Bax, Cyclin D1 and p21 were determined by western blotting. Data are representative of three independent experiments (mean and SEM in a, c, e, g)